SIG | Neuropharmacology: Integrative Epilepsy Care: Modern Meds, CAM, and International Perspective

Tuesday, December 8, 2026 at 9:00 AM to 10:30 AM · 1 hr. 30 min. (America/Denver)
Special Interest Group

Information

The Neuropharmacology SIG practically approaches the use of newer anti-seizure medications and complementary and alternative medicines for patients with epilepsy, including implications of international availability of ASMs, a deep exploration of drug-drug interactions, cost considerations, and interactive case discussions shaped by practical experience. FDA approvals of newer ASMs, such as stiripentol, fenfluramine, cannabidiol, and cenobamate, have advanced our knowledge of use for specific patient groups and deepened our understanding of drug-drug interactions. Concurrently, complementary and alternative treatments for epilepsy and epilepsy comorbidities have become more widespread, with prevalent clinician skepticism and mismatched patient expectations.
Learning Objective 1
Explore complex drug-drug interactions, cost effectiveness, and practical considerations with the use of newer anti-seizure medications (such as fenfluramine, cenobamate, cannabidiol, and stiripentol)
Learning Objective 2
Learn how to assess risks and benefits of complementary and alternative medications and determine when they may or may not be appropriate for a patient
Learning Objective 3
Discuss the rational concurrent use of multiple anti-seizure medications with emphasis on side effects, use in specific epilepsy syndromes, and implications for lower resource settings
Target Audience
CliniciansFellows/TraineesAdvanced Practice Providers (APPs)NursesPharmacistsScientists/Researchers
Career Stage
Early Career (typically 0-5 years from completion of training)Mid-Career (typically 6-15 years from completion of trainingSenior (typically >15 years from completion of training)
Demographics
ClinicalYoung ProfessionalsResearchFirst-time Attendee
Session Content Includes
and Inclusion (DEI)DiversityEquityPatient PerspectivePediatric
Session ID
NEUROPHARMSIG26
Presentation Id
3452247
Event ID
24056
Session Type
Session